The Combination of Adebrelimab and TP Regimen for Neoadjuvant Therapy

The goal of this clinical trial is to investigate the effectiveness and safety of the combination of Adebrelimab and the TP regimen as neoadjuvant therapy for patients with clinical IVB stage oral squamous cell carcinoma. The main question it aims to answer is: "Does treatment with Adebrelimab combined with the TP regimen improve outcomes in patients with clinical IVB stage oral squamous cell carcinoma compared to standard therapy alone?" Participants will receive treatment with Adebrelimab combined with the TP regimen, followed by surgery after 2 cycles of neoadjuvant therapy. Subsequently, radiotherapy and chemotherapy combined with immunotherapy will be chosen based on the patient's condition, with a total follow-up of two years.